Trials / Completed
CompletedNCT04253509
Liquid Biopsy Using Methylation Sequencing for Lung Cancer
Clinical Utility of Circulating Tumor DNA Methylation in the Diagnosis of Primary Lung Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 280 (actual)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 15 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate the utility of circulating tumor DNA (ctDNA) methylation sequencing in the diagnosis of primary lung cancer.
Detailed description
Plasma sample of patients with and without lung cancer will be collected and analyzed using methylation-sensitive enzyme sequencing method. Diagnostic performance of ctDNA methylation sequencing will be compared with that of tumor markers (CEA, Cyfra 21-1, and NSE) combined.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Circulating Tumor DNA Methylation Sequencing | Whole blood (21mL) collection through venipuncture. Analysis of tumor markers and ctDNA methylation sequencing. |
Timeline
- Start date
- 2020-02-03
- Primary completion
- 2022-01-31
- Completion
- 2022-01-31
- First posted
- 2020-02-05
- Last updated
- 2022-02-08
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04253509. Inclusion in this directory is not an endorsement.